Implication of microRNAs in the pathogenesis of MDS

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3170-3179

  Fang, Jing ^a   Varney, Melinda ^a   Starczynowski, Daniel T ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Microarray; MicroRNA; Myelodysplastic syndrome

Indexed keywords

MICRORNA; MICRORNA 103; MICRORNA 10A; MICRORNA 10B; MICRORNA 126; MICRORNA 140; MICRORNA 145; MICRORNA 146A; MICRORNA 150; MICRORNA 155; MICRORNA 15A; MICRORNA 181A; MICRORNA 193; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 224; MICRORNA 299; MICRORNA 323; MICRORNA 335; MICRORNA 342; MICRORNA 365; MICRORNA 368; MICRORNA 378; MICRORNA 382; MICRORNA 483; MICRORNA 558; MICRORNA 632; MICRORNA 636; UNCLASSIFIED DRUG;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; BIOGENESIS; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME DELETION 5; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE CLASSIFICATION; DISEASE COURSE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR PATHOLOGY; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REVIEW; RISK ASSESSMENT; TRISOMY 8; WORLD HEALTH ORGANIZATION;

EID: 84862516713     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023170     Document Type: Review

References (110)

1. Scott BL, Deeg HJ. Myelodysplastic syndromes. Annu Rev Med.2011: 61: 345-58.
2. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001: 73: 405-10.
3. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2011: 24: 287-94.
4. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009: 361: 1872-85.
5. Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol.2010: 150: 131-43.
6. Sekeres MA. Are we nearer to curing patients with MDS?. Best Pract Res Clin Haematol 2010: 23: 481-7.
7. Vardiman JW, Thiele J, Arber DA, Brunning RD, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood.2009: 114: 937-51.
8. Cazzola M, Malcovati L. Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 2010: 24: 459-68.
9. Gondek LP, Tiu R, O'Keefe C L, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008: 111: 1534-42.
10. Mohamedali A, aken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007: 110: 3365-73.
11. Starczynowski DT, Vercauteren S, Sung S, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Leuk Res 2010.
12. Starczynowski DT, Vercauteren S, Telenius A, et al. High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 2008: 112: 3412-24.
13. Bejar R, Ebert BL. The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010: 24: 295-315.
14. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006: 355: 1456-65.
15. Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998: 91: 1008-15.
16. Corey SJ, Minden MD, Barber DL, et al. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007: 7: 118-29.
17. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000: 96: 2012-21.
18. Nilsson L, Eden P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood 2007: 110: 3005-14.
19. Tiu R, Gondek L, O'Keefe C, et al. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia 2007: 21: 1648-57.
20. Hast R, Eriksson M, Widell S, et al. Neutrophil dysplasia is not a specific feature of the abnormal chromosomal clone in myelodysplastic syndromes. Leuk Res 1999: 23: 579-84.
21. Bigoni R, Cuneo A, Milani R, et al. Multilineage involvement in the 5q-syndrome: a fluorescent in situ hybridization study on bone marrow smears. Haematologica 2001: 86: 375-81.
22. Emura I. High incidence of apoptosis in peripheral blood of myelodysplastic syndrome patients determined by Papanicolaou-stained preparations. Lab Hematol 2003: 9: 42-6.
23. Gyan E, Frisan E, Beyne-Rauzy O, et al. Spontaneous and Fasinduced apoptosis of low-grade MDS erythroid precursors involves the endoplasmic reticulum. Leukemia 2008: 22: 1864-73.
24. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007: 35: 1739-46.
25. Economopoulou C, Pappa V, Kontsioti F, et al. Analysis of apoptosis regulatory genes expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS). Leuk Res 2008: 32: 61-9.
26. Stifter G, Heiss S, Gastl G, et al. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 2005: 75: 485-91.
27. Gersuk GM, Beckham C, Loken MR, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998: 103: 176-88.
28. Gersuk GM, Lee JW, Beckham CA, et al. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996: 88: 1122-3.
29. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med 2010: 16: 59-66.
30. Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011: 117: 2567-76.
31. McGowan KA, Pang WW, Bhardwaj R, et al. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome. Blood 2011:118: 3622-33
32. Pellagatti A, Marafioti T, Paterson JC, et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q-syndrome. Blood 2010: 115: 2721-3.
33. Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000: 96: 3932-8.
34. Rajapaksa R, Ginzton N, Rott LS, et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996: 88: 4275-87.
35. Boudard D, Vasselon C, Bertheas MF, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002: 70: 115-25.
36. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997: 89: 2079-88.
37. Parker JE, Fishlock KL, Mijovic A, et al. 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of proversus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998: 103: 1075-82.
38. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010: 16: 49-58.
39. Starczynowski DT, Morin R, McPherson A, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011: 117: 595-607.
40. Starczynowski DT, Kuchenbauer F, Wegrzyn J, et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol 2010: 39: 167-178 e4.
41. Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008: 68: 10349-57.
42. Rathinam C, Thien CB, Flavell RA, et al. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010: 18: 341-52.
43. Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 2010: 24: 317-30.
44. Szmigielska-Kaplon A, Robak T. Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia. Curr Cancer Drug Targets 2011 [Epub ahead of print]
45. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2010: 25: 226-35.
46. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009: 113: 1315-25.
47. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009: 360: 2289-301.
48. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011: 20: 11-24.
49. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011: 20: 25-38.
50. Li Z, Cai X, Cai C, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011 [Epub ahead of print]
51. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009: 145: 788-800.
52. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010: 151: 365-75.
53. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004: 116: 281-97.
54. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006: 20: 515-24.
55. Hinske LC, Galante PA, Kuo WP, Ohno-Machado L. A potential role for intragenic miRNAs on their hosts' interactome. BMC Genomics 2010: 11: 533.
56. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004: 23: 4051-60.
57. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004: 10: 1957-66.
58. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature 2004: 432: 231-5.
59. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005: 123: 631-40.
60. Orkin SH, Zon LI. SnapShot: hematopoiesis. Cell 2008: 132: 712.
61. Havelange V, Garzon R. MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol 2010: 85: 935-42.
62. Schotte D, Pieters R, Den Boer ML. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2011 [Epub ahead of print]
63. Georgantas RW 3rd, Hildreth R, Morisot S, et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circ it diagram of differentiation control. Proc Natl Acad Sci USA 2007: 104: 2750-5.
64. Liao R, Sun J, Zhang L, et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 2008: 104: 805-17.
65. Ooi AG, Sahoo D, Adorno M, et al. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets. Proc Natl Acad Sci USA. 2010:107:21505-10.
66. Guo S, Lu J, Schlanger R, et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA 2010: 107: 14229-34.
67. Merkerova M, Vasikova A, Belickova M, Bruchova H. MicroRNA expression profiles in umbilical cord blood cell lineages. Stem Cells Dev 2010: 19: 17-26.
68. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002: 99: 15524-9.
69. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005: 102: 13944-9.
70. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004: 101: 2999-3004.
71. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005: 435: 834-8.
72. Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 2007: 104: 19971-6.
73. Cammarata G, Augugliaro L, Salemi D, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 2010: 85: 331-9.
74. Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008: 105: 15535-40.
75. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008: 358: 1919-28.
76. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008: 111: 5078-85.
77. Garzon R, Garofalo M, Martelli MP, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008: 105: 3945-50.
78. Sokol L, Caceres G, Volinia S, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol.2011: 153: 24-32.
79. Zhao JL, Rao DS, Boldin MP, et al. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011: 108: 9184-9.
80. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med 2011: 208: 1189-201.
81. Yang K, He YS, Wang XQ, et al. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett 2011: 585: 854-60.
82. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006: 103: 12481-6.
83. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005: 120: 635-47.
84. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007: 67: 9762-70.
85. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005: 102: 18081-6.
86. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA 2006: 103: 5078-83.
87. Erdogan B, Facey C, Qualtieri J, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011: 39(9):915-926
88. Hussein K, Theophile K, Busche G, et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2010: 34: 328-34.
89. Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT. Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis, 2009: 43: 81-7.
90. Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008: 93: 1009-16.
91. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007: 35: 1657-67.
92. Pons A, Nomdedeu B, Navarro A, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009: 50: 1854-9.
93. Dostalova Merkerova M, Krejcik Z, Votavova H, et al. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011: 19: 313-9.
94. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008: 205: 585-94.
95. Hussein K, Theophile K, Busche G, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010: 34: 1169-74.
96. Votavova H, Grmanova M, Dostalova Merkerova M, et al. Differential expression of microRNAs in CD34+ cells of 5q-syndrome. J Hematol Oncol 2010: 4: 1.
97. Oliva EN, Nobile F, Iacopino P, et al. Increases in miRNA-145 and miRNA-146a expression in patients with IPSS lower-risk myelodysplastic syndromes and del(5q) treated with lenalidomide. ASH Annual Meeting 2010 116: Abstracts 3631.
98. Kumar M, Narla A, Nonami A, et al. Coordinate loss of a microRNA Mir 145 and a protein-coding gene RPS14 cooperate in the pathogenesis of 5q-syndrome. ASH Annual Meeting 2009 114: Abstracts 947.
99. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q-syndrome. Br J Haematol 2007: 139: 578-89.
100. Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010: 142: 914-29.
101. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009: 4: e6816.
102. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007: 26: 745-52.
103. Bousquet M, Quelen C, Rosati R, et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 2008: 205: 2499-506.
104. Gozzetti A, Tozzuoli D, Crupi R. et al. A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement. Cancer Genet Cytogenet 2003: 144: 177-8.
105. Yamamoto K, Nagata K, Morita Y, et al. New complex t(2;11;17)(p21;q23;q11), a variant form of t(2;11), associated with del(5)(q23q32) in myelodysplastic syndrome-derived acute myeloblastic leukemia. Cancer Genet Cytogenet 2002: 137: 119-23
106. O'Connell RM, Chaudhuri, AA, Rao DS, et al. MicroRNAs enriched in hematopoietic stem cells differentially regulate longterm hematopoietic output. Proc Natl Acad Sci USA 2010: 107: 14235-40.
107. Beck D, Ayers S, Wen J, et al. Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes. BMC Med Genomics 2011: 4: 19.
108. Jung M, Schaefer A, Steiner I, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 2010: 56: 998-1006.
109. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005: 352: 549-57.
110. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009: 106: 12974-9